<code id='2271700F00'></code><style id='2271700F00'></style>
    • <acronym id='2271700F00'></acronym>
      <center id='2271700F00'><center id='2271700F00'><tfoot id='2271700F00'></tfoot></center><abbr id='2271700F00'><dir id='2271700F00'><tfoot id='2271700F00'></tfoot><noframes id='2271700F00'>

    • <optgroup id='2271700F00'><strike id='2271700F00'><sup id='2271700F00'></sup></strike><code id='2271700F00'></code></optgroup>
        1. <b id='2271700F00'><label id='2271700F00'><select id='2271700F00'><dt id='2271700F00'><span id='2271700F00'></span></dt></select></label></b><u id='2271700F00'></u>
          <i id='2271700F00'><strike id='2271700F00'><tt id='2271700F00'><pre id='2271700F00'></pre></tt></strike></i>

          Home / entertainment / leisure time

          leisure time


          leisure time

          author:fashion    Page View:46888
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In